SciSparc Unit Neurothera Labs And Clearmind Medicine Publish U.S. Patent Application For A Novel Combination Of 3,4-Methylenedioxymethamphetamine And N-Acylethanolamines For Use In Methods Of Treating Post-Traumatic Stress Disorder, Anxiety And Eating Disorders

Clearmind Medicine Advances Its IP Portfolio With Publication In U.S. Of Its Patent Application For Novel Combination Of 3,4-Methylenedioxymethamphetamine And N-Acylethanolamines To Treat Post-Traumatic Stress Disorder

Clearmind Medicine Makes Clinical Progress in Alcohol Addiction Treatment Trial

Clearmind Medicine advances the CMND-100 clinical trial for alcohol use disorder to Parts B and C following positive Phase A safety data.

Clearmind Medicine Says DSMB Unanimously Approved Advancing Phase 1/2 Trial Of CMND-100 To Parts B And C In Alcohol Use Disorder Patients And Healthy Participants

SciSparc Adds Prof. Carmel Domshlak To Newly Established Scientific Advisory Board For AI And Cybersecurity, Effective September 1

The addition of leading AI researcher further strengthens SciSparc’s scientific and technical foundation as the Company advances its strategic focus on the Agentic AI marketTEL AVIV, Israel, Aug. 26, 2026 (GLOBE

SciSparc shares are trading higher. The company announced its majority-owned subsidiary, NeuroThera Labs, has completed two tranches of non-brokered private placements, raising aggregate gross proceeds of C$5.4 million.

16.86 -1.64 [-8.86%]

SciSparc Invests C$2.7 Million In NeuroThera Financing, Raising Stake To 44.6% Valued At ~C$30 Million

SciSparc Invests C$2.7 million and holds approximately 44.6% of NeuroThera’s issued and outstanding common shares following the financingTEL AVIV, Israel, Aug. 18, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC)